Strainprint's efficacy ratings rest on real patient use data, which is a genuine contribution, but the platform sells analytics access to the very producers whose strains it rates, the scoring methodology is not publicly documented, and commercial ties are not disclosed near patient-facing ratings — limiting how much a reader can trust the scores as independent.
What it's really for To build a proprietary cannabis outcomes dataset and monetize it as a research and analytics product sold to the cannabis industry and health sector, with a patient app as the data-collection front end.
What our grade covers The grade on this page is about Cannabis strain efficacy ratings for medical conditions, based on aggregated patient-reported outcomes, not everything the site does.
Medium Scoring Confidence Mostly sourced, but a detail or two still needs a primary source, so the grade could shift slightly.
Strainprint's homepage "Trusted By" section lists cannabis producers Tilray, Aurora, Cannatrek, and MUV as paying clients for analytics and research access — the same companies whose strains are rated by patients in the app. Revenue from those producers funds the platform, creating a structural conflict between rating independence and commercial relationships.
Source →- Operating since
- 2016 (10 years) · source
- What it costs you
- Free to read The reviews are free to read.
- How they make money
- Free app for patients; B2B revenue from analytics dashboard subscriptions, custom research reports, and data licensing sold to cannabis producers, retailers, and health institutions.
- What they do
- Patients log cannabis sessions and symptom outcomes via a mobile app; Strainprint aggregates those self-reported outcomes into strain efficacy ratings tied to specific medical conditions, then sells the underlying analytics and research reports to cannabis producers, retailers, and health researchers.
- What to watch for
- Does not publish its scoring methodology, does not disclose near patient-facing ratings that the producers whose products are rated are paying data customers, and does not use lab testing or independent clinical verification — all efficacy scores are self-reported by app users with no third-party audit.
- Composite score
- 2.20 / 5.00 → grade C
How the grade was reached
Does the site take money from the very entities it ranks? Pay-for-placement, vendor-funded data, and affiliate commissions all pull this down. The less the ranking can be bought, the higher the score.
What is the ranking actually built on? Hands-on testing scores highest, then verified first-hand reviews, then opinion or popularity surveys and self-reported figures, then pay-to-rank, which scores lowest.
Is the methodology published, specific, and reproducible? Can a reader see how a given rank was reached, or is it a black box?
Are commercial relationships, sponsorships, and affiliate arrangements disclosed clearly and near the rankings themselves, rather than buried?
How hard is it to game? Controls against fake reviews, solicited reviews, and vendor gaming raise this; an open box anyone can stuff lowers it.
Evidence
- Strainprint's homepage 'Trusted By' section names Tilray, Aurora, Cannatrek, MUV, and Bayer as clients — cannabis producers whose products appear in patient efficacy ratings — indicating the platform sells data and analytics back to ranked entities. Source: Strainprint homepage →
- The about page states Strainprint was founded in Toronto in 2016 and describes itself as providing 'demand-side cannabis data and analytics' to patients, practitioners, industry, and government, with privacy-compliant anonymized data. Source: Strainprint About page →
- The research page states ratings are drawn from 'cannabis consumption data to understand how people use cannabis for different medical indications and how they rate the efficacy of the products they use,' but provides no published formula or audit trail for how raw session logs become efficacy scores. Source: Strainprint Research page →
- No advertiser-disclosure or conflict-of-interest page was found in up to four pages reviewed; commercial relationships with producers are not disclosed adjacent to patient-facing strain ratings. Source: Strainprint site review (no disclosure page found) →